RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner
Open accessPublished version of a preprint
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Lymph node metastasis is the main cause of poor prognosis of head and neck squamous carcinoma (HNSCC) patients. N6-methyladenosine (m6A) RNA modification is an emerging epigenetic regulatory mechanism for gene expression, and as a novel m6A reader protein, IGF2BP2 has been implicated in tumor progression and metastasis. However, not much is currently known about the functional roles of IGF2BP2 in HNSCC, and whether IGF2BP2 regulates lymphatic metastasis through m6A modification in HNSCC remains to be determined. Methods: The expression and overall survival (OS) probability of m6A-related regulators in HNSCC were analyzed with The Cancer Genome Atlas (TCGA) dataset and GEPIA website tool, respectively. The expression levels of IGF2BP2 were measured in HNSCC tissues and normal adjacent tissues. To study the effects of IGF2BP2 on HNSCC cell metastasis in vitro and in vivo, gain- and loss- of function methods were employed. RIP, MeRIP, luciferase reporter and mRNA stability assays were performed to explore the epigenetic mechanism of IGF2BP2 in HNSCC. Results: We investigated 20 m6A-related regulators in HNSCC and discovered that only the overexpression of IGF2BP2 was associated with a poor OS probability and an independent prognostic factor for HNSCC patients. Additionally, we demonstrated that IGF2BP2 was overexpressed in HNSCC tissues, and significantly correlated to lymphatic metastasis and poor prognosis. Functional studies have shown that IGF2BP2 promotes both HNSCC cell migration as well as invasion via the epithelial-mesenchymal transition (EMT) process in vitro, and IGF2BP2 knockdown significantly inhibited lymphatic metastasis and lymphangiogenesis in vivo. Mechanistic investigations revealed that Slug, a key EMT-related transcriptional factor, is the direct target of IGF2BP2, and essential for IGF2BP2-regulated EMT and metastasis in HNSCC. Furthermore, we demonstrated that IGF2BP2 recognizes and binds the m6A site in the coding sequence (CDS) region of Slug and promotes its mRNA stability. Conclusions: Collectively, our study uncovers the oncogenic role and potential mechanism of IGF2BP2, which serves as a m6A reader, in controlling lymphatic metastasis and EMT in HNSCC, suggesting that IGF2BP2 may act as a therapeutic target and prognostic biomarker for HNSCC patients with metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“The process of EMT is characterized by the loss of cell adhesion and epithelial markers, like E-cadherin, which is a fundamental event for EMT; and results in the gain of enhanced invasive capacities and mesenchymal markers, including N-cadherin and vimentin [36].”
BackgroundRecognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., Zhao, B. S., Mesquita, A., Liu, C., Yuan, C. L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0045-z · Cited by 2,997
Self-citationTGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Reading, writing and erasing mRNA methylation
Zaccara, S., Ries, R. J., & Jaffrey, S. R. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0168-5 · Cited by 2,597 · cited 3×
“In this dynamic process, the fate and biological function of m6A-modified RNAs mainly relies on the m6A binding proteins (“readers”) [23, 24].”
BackgroundPuram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Non-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
Degrauwe, N., Suvà, M.-L., Janiszewska, M., Riggi, N., & Stamenkovic, I. (2016) · Genes & Development · doi:10.1101/gad.287540.116 · Cited by 324
Xu, X., Yu, Y., Zong, K., Lv, P., & Gu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1470-y · Cited by 203 · cited 1×
“Previous studies have reported that IGF2BP2 is amplified and overexpressed in multiple cancers, and closely associated with clinical characteristics and poor prognosis [15, 52, 53].”
BackgroundDai, N., Zhao, L., Wrighting, D., Krämer, D., Majithia, A., Wang, Y., Cracan, V., Borges-Rivera, D., Mootha, V. K., Nahrendorf, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.006 · Cited by 188
Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer
Recouvreux, M. V., Moldenhauer, M. R., Galenkamp, K. M. O., Jung, M., James, B., Zhang, Y., Lowy, A., Bagchi, A., & Commisso, C. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200388 · Cited by 181 · cited 1×
“Although the roles of Slug in promoting EMT have been well studied [39, 43], we further investigated the roles of Slug in IGF2BP2-regulated EMT of cancer cells.”
Background
Research works printed but not linked: 48
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. · DOI · Paper page
- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. · DOI · Paper page
- Chow LQM. Head and neck Cancer. N Engl J Med. 2020;382(1):60–72. · DOI · Paper page
- Galloway TJ, Ridge JA. Management of Squamous Cancer Metastatic to cervical nodes with an unknown primary site. J Clin Oncol. 2015;33(29):3328–37. · doi:10.1200/jco.2015.61.0063
- Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–83. · DOI · Paper page
- Karam SD, Raben D. Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol. 2019;20(8):e404–e16. · DOI
- Ferris RL. Immunology and immunotherapy of head and neck Cancer. J Clin Oncol. 2015;33(29):3293–304. · DOI · Paper page
- Liu HB, Muhammad T, Guo Y, Li MJ, Sha QQ, Zhang CX, et al. RNA-binding protein IGF2BP2/IMP2 is a critical maternal activator in early zygotic genome activation. Adv Sci (Weinh). 2019;6(15):1900295. · DOI · Paper page
- Wang J, Chen L, Qiang P. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer Cell Int. 2021;21(1):99. · DOI · Paper page
- Cao J, Mu Q, Huang H. The roles of insulin-like growth factor 2 mRNA-binding protein 2 in Cancer and Cancer stem cells. Stem Cells Int. 2018;2018:4217259.
- Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, et al. An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev Cell. 2012;23(6):1176–88. · DOI · Paper page
- Kessler SM, Laggai S, Barghash A, Schultheiss CS, Lederer E, Artl M, et al. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis. 2015;6:e1894. · DOI · Paper page
- Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200. · DOI · Paper page
- Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42. · DOI · Paper page
- Frye M, Harada BT, Behm M, He C. RNA modifications modulate gene expression during development. Science. 2018;361(6409):1346–9. · DOI · Paper page
- Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74(4):640–50. · DOI · Paper page
- Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m (6) a modification. Trends Genet. 2020;36(3):177–88. · DOI · Paper page
- Zhao Y, Shi Y, Shen H, Xie W. M (6) A-binding proteins: the emerging crucial performers in epigenetics. J Hematol Oncol. 2020;13(1):35. · DOI · Paper page
- Liao S, Sun H, Xu C. YTH domain: a family of N (6)-methyladenosine (m (6) a) readers. Genomics Proteomics Bioinformatics. 2018;16(2):99–107. · DOI · Paper page
- Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19(1):88. · DOI · Paper page
- Zhao W, Qi X, Liu L, Ma S, Liu J, Wu J. Epigenetic regulation of m (6) a modifications in human Cancer. Mol Ther Nucleic Acids. 2020;19:405–12. · DOI · Paper page
- Guo H, Wang B, Xu K, Nie L, Fu Y, Wang Z, et al. M (6) a reader HNRNPA2B1 promotes esophageal Cancer progression via up-regulation of ACLY and ACC1. Front Oncol. 2020;10:553045. · DOI
- Wang Q, Guo X, Li L, Gao Z, Su X, Ji M, et al. N (6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):911. · DOI · Paper page
- Zhang C, Hu J, Li H, Ma H, Othmane B, Ren W, et al. Emerging biomarkers for predicting bladder Cancer lymph node metastasis. Front Oncol. 2021;11:648968. · DOI
- Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742–57. · DOI · Paper page
- Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19(11):1450–64. · DOI · Paper page
- Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26. · DOI · Paper page
- Goossens S, Vandamme N, Van Vlierberghe P, Berx G. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017;1868(2):584–91. · DOI · Paper page
- Cobaleda C, Perez-Caro M, Vicente-Duenas C, Sanchez-Garcia I. Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet. 2007;41:41–61. · DOI · Paper page
- Zhou W, Gross KM, Kuperwasser C. Molecular regulation of Snai2 in development and disease. J Cell Sci. 2019;132(23). · DOI
- D'Uva G, Bertoni S, Lauriola M, De Carolis S, Pacilli A, D'Anello L, et al. Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One. 2013;8(11):e80742. · DOI
- Jung CH, Kim J, Park JK, Hwang SG, Moon SK, Kim WJ, et al. Mdm2 increases cellular invasiveness by binding to and stabilizing the slug mRNA. Cancer Lett. 2013;335(2):270–7. · DOI
- Yu D, An X, Fan W, Wang X, He Y, Li B. PNUTS mediates ionizing radiation-induced CNE-2 nasopharyngeal carcinoma cell migration, invasion, and epithelial-mesenchymal transition via the PI3K/AKT signaling pathway. Onco Targets Ther. 2019;12:1205–14. · doi:10.2147/ott.s188571
- Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, et al. M (6) a mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074–83. · DOI · Paper page
- Wang Y, Yang Z. A Gleason score-related outcome model for human prostate cancer: a comprehensive study based on weighted gene co-expression network analysis. Cancer Cell Int. 2020;20:159. · DOI
- Li Y, Lu T, Hu G. Gene sequencing and expression of Raf-1 in lymphatic metastasis of hypopharyngeal carcinoma. Cancer Biomark. 2020;28(2):181–91. · doi:10.3233/cbm-191238
- Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 2005;7(2):121–7. · DOI · Paper page
- Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer. 2003;98(2):413–23. · DOI · Paper page
- Liu L, Lin C, Liang W, Wu S, Liu A, Wu J, et al. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut. 2015;64(1):26–36. · DOI
- Dahlem C, Barghash A, Puchas P, Haybaeck J, Kessler SM. The insulin-like growth factor 2 mRNA binding protein IMP2/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic Cancer. Int J Mol Sci. 2019;20(13):3204. · DOI · Paper page
- Deng X, Jiang Q, Liu Z, Chen W. Clinical significance of an m6A reader gene, IGF2BP2, in head and neck squamous cell carcinoma. Front Mol Biosci. 2020;7:68. · DOI · Paper page
- Shah SA, Gallagher BM, Sands H. Lymphoscintigraphy of human colorectal carcinoma metastases in athymic mice by use of radioiodinated B72.3 monoclonal antibody. J Natl Cancer Inst. 1987;78(6):1069–77.
- Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014;14(3):159–72. · DOI · Paper page
- Mu Q, Wang L, Yu F, Gao H, Lei T, Li P, et al. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biol Ther. 2015;16(4):623–33. · DOI · Paper page
- Zhou Y, Zeng P, Li YH, Zhang Z, Cui Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 2016;44(10):e91. · DOI · Paper page
- Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an m (6) A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112. · DOI · Paper page
- Hou P, Meng S, Li M, Lin T, Chu S, Li Z, et al. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. J Exp Clin Cancer Res. 2021;40(1):52. · DOI · Paper page
- Karlsson MC, Gonzalez SF, Welin J, Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol. 2017;11(7):781–91. · DOI · Paper page
Cited by
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Xia, T., Dai, X., Sang, M., Zhang, X., Xu, F., Wu, J., Shi, L., Wei, J., & Ding, Q. (2024) · Advanced Science · doi:10.1002/advs.202305142 · Cited by 52
Wang, J., Zhu, M., Zhu, J., Li, J., Zhu, X., Wang, K., Shen, K., Yang, K., Ni, X., Liu, X., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01707-4 · Cited by 41
Lin, C.-W., Yang, W.-E., Su, C.-W., Lu, H.-J., Su, S.-C., & Yang, S.-F. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91786 · Cited by 24
“…of CCAR1 (Cell Division Cycle And Apoptosis Regulator 1) [39], SMAD3 (Mothers against decapentaplegic homolog 3) [40], and SNAIL2 (Snail family transcriptional repressor 2) [41] by IGF2BP2 was demonstrated to promote metastatic responses of prostate, gastric, and head and neck cancer, respectively.”
BackgroundRen, J., Huang, B., Li, W., Wang, Y., Pan, X., Ma, Q., Liu, Y., Wang, X., Liang, C., Zhang, Y., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101904 · Cited by 11
Metadata
- Authors
- Yu, D., Pan, M., Li, Y., Lu, T., Wang, Z., Liu, C., & Hu, G.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2022-01-03
- Volume
- 41
- Issue
- 1
- Pages
- 6-6
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W4220893511
- Cited by
- 120
- References
- 13
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. https://app.cochat.ai/papers/10.1186/s13046-021-02212-1
- The paper
- Yu, D., Pan, M., Li, Y., Lu, T., Wang, Z., Liu, C., & Hu, G. (2022). RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-02212-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.